- Previous Close
155.90 - Open
149.70 - Bid 150.50 x --
- Ask 153.80 x --
- Day's Range
147.00 - 149.70 - 52 Week Range
137.65 - 196.40 - Volume
17 - Avg. Volume
0 - Market Cap (intraday)
4.248B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
54.24 - EPS (TTM)
2.71 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
www.krystalbio.comRecent News: 4KB.F
View MorePerformance Overview: 4KB.F
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4KB.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4KB.F
View MoreValuation Measures
Market Cap
4.48B
Enterprise Value
3.95B
Trailing P/E
57.39
Forward P/E
22.88
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.62
Price/Book (mrq)
5.26
Enterprise Value/Revenue
14.97
Enterprise Value/EBITDA
39.57
Financial Highlights
Profitability and Income Statement
Profit Margin
30.69%
Return on Assets (ttm)
6.88%
Return on Equity (ttm)
10.34%
Revenue (ttm)
290.52M
Net Income Avi to Common (ttm)
89.16M
Diluted EPS (ttm)
2.71
Balance Sheet and Cash Flow
Total Cash (mrq)
597.52M
Total Debt/Equity (mrq)
0.77%
Levered Free Cash Flow (ttm)
92.96M